

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 12578

Title: Efficacy of S-1 vs Capecitabine for The treatment of Gastric Cancer: A Meta-Analysis

Reviewer code: 02977393

Science editor: Yuan Qi

Date sent for review: 2014-07-16 16:49

Date reviewed: 2014-08-06 14:59

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

Comments to author The authors performed a meta-analysis to systematically compare the effects between S-1 and capecitabine against gastric cancer. However, there are some weaknesses as described belows. 1) The results of "OR" seem insufficient to help evaluate patients' prognosis. In addition, Parmar, study is intended to extract the survival data of HR. The authors should check and explain it. 2) The results do not match Figure 2. The authors should check and explain it. 3) Miss conclusion in abstract. There are also other small weaknesses. Please check and revise it.